EUCTR2012-005772-34-SE进行中（未招募）不适用
A randomised, double-blind, placebo-controlled proof-of concept study of the efficacy of gevokizumab 60mg subcutaneously every 4 weeks over 24 weeks in the treatment of patients with polymyositis, dermatomyositis or necrotizing autoimmune myopathy disease
Institut de Recherches Internationales Servier (IRIS)0 个研究点目标入组 40 人开始时间: 2013年6月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Active polymyositis or dermatomyositis or necrotizing autoimmune myopathy intolerant or resistant or dependent to systemic oral corticosteroids,
- •- With a stable background treatment of oral corticosteroid if any and / or a stable dose of immunosuppressive agent if any.
- •- Male or female, age = 18 (or legal age of majority in the country),
- •- Weight = 40 kg and = 125 kg at selection,
- •- For subjects with reproductive potential, a willingness to use highly effective contraceptive measures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •- Juvenile dermatomyositis, drug induced myositis, severity criteria such as severe cardiovascular or pulmonary involvement or myositis damage, congenital myopathy, inclusion body myositis, cancer- associated myositis or DM diagnosed for less than 1 year,
- •- Impossibility to perform muscle biopsy for PM, DM sine dermatitis and NAM patients (if required),
- •- Non-ambulatory patients,
- •- Fibromyalgia of type I,
- •- Joint disease or other musculoskeletal condition,
- •- Active TB disease,
- •- History of severe allergic or anaphylactic reactions to monoclonal antibodies,
- •- History of malignancy within 5 years prior to selection,
- •- Known immunodeficiency,
- •- Infectious disease,
- •- Pregnancy, breastfeeding or possibility to become pregnant during the study
研究者
相似试验
进行中（未招募）
不适用
A placebo-controlled, proof-of concept study of the efficacy of gevokizumab subcutaneously over 24 weeks in the treatment of patients with polymyositis, dermatomyositis or necrotizing autoimmune myopathy diseasePolymyositis / Dermatomyositis/ necrotizing autoimmune myopathyMedDRA version: 17.1Level: PTClassification code 10012503Term: DermatomyositisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 17.1Level: PTClassification code 10036102Term: PolymyositisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2012-005772-34-DEInstitut de Recherches Internationales Servier (IRIS)40
进行中（未招募）
1 期
A placebo-controlled, proof-of concept study of the efficacy and safety of gevokizumab in the treatment of patients with giant cell arteritisGiant cell arteritisEUCTR2013-002778-38-ITInstitut de Recherches Internationales Servier (IRIS)50
进行中（未招募）
不适用
A placebo-controlled, proof-of concept study of the efficacy and safety of gevokizumab in the treatment of patients with giant cell arteritisGiant cell arteritisEUCTR2013-002778-38-IEInstitut de Recherches Internationales Servier (IRIS)50
进行中（未招募）
不适用
A placebo-controlled, proof-of concept study of the efficacy of gevokizumab subcutaneously over 24 weeks in the treatment of patients with polymyositis or dermatomyositis diseaseEUCTR2012-005772-34-ESaboratorios Servier S.40
进行中（未招募）
1 期
A placebo-controlled, proof-of concept study of the efficacy of gevokizumab subcutaneously over 24 weeks in the treatment of patients with polymyositis or dermatomyositis diseasePolymyositis / DermatomyositisMedDRA version: 14.1Level: PTClassification code 10012503Term: DermatomyositisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 14.1Level: PTClassification code 10036102Term: PolymyositisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2012-005772-34-ITInstitut de Recherches Internationales Servier (IRIS)40